Study of AG10 in Amyloid Cardiomyopathy

Phase 2

Completed

• Conditions: Familial ATTR-CM (ATTRm-CM, or FAC); Wild-type ATTR-CM (ATTRwt-CM)
• Interventions: Drug: AG10; Drug: Placebo Oral Tablet

• Registration Number: NCT03458130
• Lead Sponsor: Eidos Therapeutics, a BridgeBio company

Brief Summary

This prospective, randomized, multicenter, double-blind, parallel group, placebo-controlled, dose-ranging study will evaluate the safety, tolerability, PK (Pharmacokinetic) and PD (Pharmacodynamic) of AG10 compared to placebo administered on a background of stable heart failure therapy. Screening and randomization will be followed by a 28-day blinded, placebo-controlled treatment period.

Detailed Description

A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients with Symptomatic Transthyretin Amyloid Cardiomyopathy.

The primary objective of this study is to evaluate the safety and tolerability of AG10 administered to adult patients with symptomatic transthyretin amyloid cardiomyopathy (ATTRCM).

This study will be a Phase 2, randomized, placebo-controlled, dose-ranging study in 45 male and/or female patients with symptomatic ATTR-CM aged 18 through 90 years.

If all doses are well tolerated, the duration of each patient's participation in the study will be 28 days of treatment. In addition, there will be a 28-day screening period before treatment and a 30-day follow-up period before the final Follow-up Visit.

This prospective, randomized, multicenter, double-blind, parallel group, placebo-controlled, dose-ranging study will evaluate the safety, tolerability, PK and PD of AG10 compared to placebo administered on a background of stable heart failure therapy. Screening and randomization will be followed by a 28-day blinded, placebo-controlled treatment period. secondary objectives of this study are: to characterize the pharmacokinetics (PK) of AG10 administered orally twice daily in patients with symptomatic ATTRCM, and to describe the pharmacodynamic (PD) properties of AG10 as assessed by established assays of transthyretin (TTR) stabilization, including Fluorescent Probe Exclusion (FPE) assay and Western blot, and to describe the Pharmacokinetic Pharmacodynamic (PKPD) relationship of AG10 in adult patients with symptomatic ATTRCM.

Eligible patients will be randomized in a 1:1:1 ratio to placebo or one of two different doses of AG10 administered twice daily. A minimum of 30% of patients enrolled will be mutant ATTR-CM.

Study Timeline

• Study First Submitted: 2018-02-07
• Study First Submitted QC: 2018-03-01
• Study First Posted: 2018-03-08
• Study Start: 2018-04-27
• Primary Completion: 2018-10-05
• Study Completion: 2018-10-05
• Disposition First Submitted: 2019-11-15
• Results First Submitted: 2022-09-12
• Status Verified: 2022-10
• Results First Submitted QC: 2022-10-24
• Disposition First Submitted QC: 2022-10-24
• Last Update Submitted: 2022-10-24
• Results First Posted: 2022-11-16
• Disposition First Posted: 2022-11-16
• Last Update Posted: 2022-11-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 49

Inclusion Criteria

1. Have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures.
2. Be a male or female ≥18 to ≤90 years of age.
3. Have an established diagnosis of ATTR-CM with either wild-type transthyretin or a variant transthyretin genotype (assessed by genotyping, with patients with concurrent monoclonal gammopathy of undetermined significance requiring a confirmatory test using mass spectrometry) as defined by either positive endomyocardial biopsy or positive technetium pyrophosphate scan.
4. Have a history of heart failure evidenced by at least one prior hospitalization for heart failure or clinical evidence of heart failure (without hospitalization) requiring medical management.
5. Have New York Heart Association (NYHA) Class II-III symptoms.
6. Male patients and female patients of childbearing potential who engage in heterosexual intercourse must agree to use appropriate method(s) of contraception.
7. For patients taking cardiovascular medical therapy, with the exception of diuretic dosing, must be on stable doses (defined as no greater than 50% dose adjustment and no categorical changes of medications) for at least 2 weeks prior to Screening.

Exclusion Criteria

1. Acute myocardial infarction, acute coronary syndrome or coronary revascularization within 90 days prior to Screening.
2. Experienced stroke within 90 days prior to Screening.
3. Has hemodynamic instability at Screening or Randomization that, in the judgment of the Principal Investigator (PI), would pose too great a risk for participation in the study.
4. Has estimated glomerular filtration rate (GFR) <30 mL/min/1.73 m2 at Screening.
5. Is likely to undergo heart transplantation within the next year.
6. Has confirmed diagnosis of light-chain amyloidosis.
7. Has abnormal liver function tests at Screening, defined as Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) >3 × upper limit of normal (ULN) or total bilirubin >2 × ULN.
8. Has abnormalities in clinical laboratory tests at Screening or Randomization that, in the judgment of the PI, would pose too great a risk for participation in the study.
9. Known hypersensitivity to study drug (AG10 or placebo), its metabolites, or formulation excipient
10. Current treatment with diflunisal, tafamidis, green tea, doxycycline, tauroursodeoxycholic acid (TUDCA)/Ursodiol, Patisiran or Inotersen within 14 days or 5 half-lives of the prior investigational agent (whichever is longer) prior to Screening.
11. Females who are pregnant or breastfeeding. Lactating females must agree to discontinue nursing before the study drug is administered. A negative serum pregnancy test at Screening and a negative urine pregnancy test at Randomization visit are required for female patients of childbearing potential.
12. In the judgment of the investigator, has any clinically significant ongoing medical condition that might jeopardize the patient's safety or interfere with the study, including participation in another investigational drug or investigational device study within the 30 days prior to Screening with potential residual effects that might confound the results of this study.
13. Has any laboratory abnormality or condition that, in the investigator's opinion, could adversely affect the safety of the patient or impair the assessment of study results.
14. Has any condition that, in the opinion of the investigator, would preclude compliance with the study protocol such as a history of substance abuse, alcoholism or a psychiatric condition.
15. Has participated in another investigational study within 14 days or 5 half-lives of the prior investigational agent (whichever is longer) prior to screening. Exceptions can be made in the case of observational and/or registry studies upon consultation with the Medical Monitor.
16. Current treatment with, or chronic use of, a proton pump inhibitor (PPI) or histamine-receptor 2 (H2) antagonist within 14 days or 5 half-lives of the prior agent (whichever is longer) prior to Screening.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
AG10 High Dose	AG10	AG10 800mg tablets twice daily for 28 days
AG10 Low Dose	AG10	AG10 400mg tablets twice daily for 28 days
Placebo	Placebo Oral Tablet	Placebo tablets twice daily for 28 days

Primary Outcome Measures

Name	Time	Method
Change in Diastolic Blood Pressure	Baseline to Day 28	Change in Diastolic Blood Pressure from Baseline to Day 28 (Postdose)
Change in Heart Rate	Baseline to Day 28	Change in Heart Rate from Baseline to Day 28 (Postdose)
Change in Respiratory Rate	Baseline to Day 28	Change in Respiratory Rate from Baseline to Day 28 (Postdose)
Change in Temperature	Baseline to Day 28	Change in Temperature from Baseline to Day 28
Change in Systolic Blood Pressure	Baseline to Day 28	Change in Systolic Blood Pressure from Baseline to Day 28

Secondary Outcome Measures

Name	Time	Method
Number of Participants With Threshold Levels of Overall % Stabilization >= 95% and >= 99% by Fluorescent Probe Exclusion (FPE)	Day 1 to Day 28	In specialized lab tests on patient samples that measure the stability of the healthy form of TTR, both doses of AG10 were able to reach near complete stabilization.
Pharmacokinetic (PK): Steady State Trough Concentration of AG10	Day 14 and Day 28	Non-fluctuating minimal amount of AG10 in blood at Day 14 and Day 28

Trial Locations

Locations (13)

Northwestern University; 🇺🇸 Chicago, Illinois, United States

Cleveland Clinic; 🇺🇸 Cleveland, Ohio, United States

Brigham and Women's Hospital; 🇺🇸 Boston, Massachusetts, United States

Boston University; 🇺🇸 Boston, Massachusetts, United States

Oregon Health & Science University; 🇺🇸 Portland, Oregon, United States

Mayo Clinic; 🇺🇸 Rochester, Minnesota, United States

Cedars-Sinai Medical Center; 🇺🇸 Beverly Hills, California, United States

Yale University; 🇺🇸 New Haven, Connecticut, United States

Stanford University; 🇺🇸 Palo Alto, California, United States

University of California San Francisco; 🇺🇸 San Francisco, California, United States

Columbia University; 🇺🇸 New York, New York, United States

Medical University of South Carolina; 🇺🇸 Charleston, South Carolina, United States

University of Utah; 🇺🇸 Salt Lake City, Utah, United States